Recombinant Oncorhyncin II Effect on the Treatment of Methicillin-Resistant Staphylococcus aureus Skin Infection Article Swipe
Seyedeh Fatemeh Jafari
,
Ehsanollah Ghaznavi‐Rad
,
Shohreh Fahimirad
,
Hamid Abtahi
·
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.5812/jjm.95948
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.5812/jjm.95948
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is known to be one of the most potentially pathogenic organisms in the world. Skin infections are one of the significant infections of S. aureus. Therefore, therapeutic constraints have challenged researchers to seek new strategies to produce new medicines. Antimicrobial peptides (AMPs) are a new generation of natural drugs with antimicrobial properties and high fatality potency. Oncorhyncin II AMP is a group of peptides with bacteriostatic activity and antimicrobial effect against Gram-positive and Gram-negative bacteria. Therefore, the development and promotion of antimicrobial peptides can be a new step in the treatment of skin infections due to bacterial resistant S. aureus in hospitals. Objectives: The objective of this study was to produce recombinant Oncorhyncin II protein and evaluate its antimicrobial effects on MRSA to determine the outcomes of the treatment. Methods: In this experimental study, the Oncorhyncin II Antimicrobial peptide was synthesized by the recombinant method. The effectiveness of this peptide was assessed by the minimum inhibitory concentration (MIC) test. The activity of recombinant protein against S. aureus was investigated using in vitro and in vivo experiments. Results: The effectiveness of this peptide obtained by the MIC test was 225 μg/mL. The activity test confirmed the MIC test and showed that this antimicrobial peptide has been able to reduce MRSA cell growth. All mice infected with MRSA responded positively to the protein treatment. Conclusions: According to Oncorhyncin II antimicrobial peptide activity studies, this peptide, as a new generation of antibiotics, was expected to have positive outcomes in the improvement of S. aureus skin infections. Therefore, the results of the efficacy require further studies to be confirmed.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.5812/jjm.95948
- OA Status
- diamond
- Cited By
- 26
- References
- 29
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3022277018
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3022277018Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.5812/jjm.95948Digital Object Identifier
- Title
-
Recombinant Oncorhyncin II Effect on the Treatment of Methicillin-Resistant Staphylococcus aureus Skin InfectionWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2020Year of publication
- Publication date
-
2020-05-09Full publication date if available
- Authors
-
Seyedeh Fatemeh Jafari, Ehsanollah Ghaznavi‐Rad, Shohreh Fahimirad, Hamid AbtahiList of authors in order
- Landing page
-
https://doi.org/10.5812/jjm.95948Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
diamondOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.5812/jjm.95948Direct OA link when available
- Concepts
-
Antimicrobial, Staphylococcus aureus, Microbiology, Antibiotics, Antimicrobial peptides, Medicine, Potency, Minimum inhibitory concentration, Peptide, Recombinant DNA, Bacteria, In vitro, Biology, Biochemistry, Genetics, GeneTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
26Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 8, 2024: 9, 2023: 6, 2022: 1, 2021: 2Per-year citation counts (last 5 years)
- References (count)
-
29Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3022277018 |
|---|---|
| doi | https://doi.org/10.5812/jjm.95948 |
| ids.doi | https://doi.org/10.5812/jjm.95948 |
| ids.mag | 3022277018 |
| ids.openalex | https://openalex.org/W3022277018 |
| fwci | 1.48386317 |
| type | article |
| title | Recombinant Oncorhyncin II Effect on the Treatment of Methicillin-Resistant Staphylococcus aureus Skin Infection |
| biblio.issue | 4 |
| biblio.volume | 13 |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T11103 |
| topics[0].field.id | https://openalex.org/fields/24 |
| topics[0].field.display_name | Immunology and Microbiology |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2404 |
| topics[0].subfield.display_name | Microbiology |
| topics[0].display_name | Antimicrobial Peptides and Activities |
| topics[1].id | https://openalex.org/T13326 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9987000226974487 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | Biochemical and Structural Characterization |
| topics[2].id | https://openalex.org/T11048 |
| topics[2].field.id | https://openalex.org/fields/23 |
| topics[2].field.display_name | Environmental Science |
| topics[2].score | 0.9526000022888184 |
| topics[2].domain.id | https://openalex.org/domains/3 |
| topics[2].domain.display_name | Physical Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2303 |
| topics[2].subfield.display_name | Ecology |
| topics[2].display_name | Bacteriophages and microbial interactions |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C4937899 |
| concepts[0].level | 2 |
| concepts[0].score | 0.9130550622940063 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q68541106 |
| concepts[0].display_name | Antimicrobial |
| concepts[1].id | https://openalex.org/C2779489039 |
| concepts[1].level | 3 |
| concepts[1].score | 0.8435873985290527 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q188121 |
| concepts[1].display_name | Staphylococcus aureus |
| concepts[2].id | https://openalex.org/C89423630 |
| concepts[2].level | 1 |
| concepts[2].score | 0.6781163215637207 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q7193 |
| concepts[2].display_name | Microbiology |
| concepts[3].id | https://openalex.org/C501593827 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6436254978179932 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q12187 |
| concepts[3].display_name | Antibiotics |
| concepts[4].id | https://openalex.org/C540938839 |
| concepts[4].level | 3 |
| concepts[4].score | 0.6337056159973145 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1201508 |
| concepts[4].display_name | Antimicrobial peptides |
| concepts[5].id | https://openalex.org/C71924100 |
| concepts[5].level | 0 |
| concepts[5].score | 0.6124887466430664 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[5].display_name | Medicine |
| concepts[6].id | https://openalex.org/C57992300 |
| concepts[6].level | 3 |
| concepts[6].score | 0.5679382681846619 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q2066956 |
| concepts[6].display_name | Potency |
| concepts[7].id | https://openalex.org/C176947019 |
| concepts[7].level | 3 |
| concepts[7].score | 0.5075477361679077 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q597889 |
| concepts[7].display_name | Minimum inhibitory concentration |
| concepts[8].id | https://openalex.org/C2779281246 |
| concepts[8].level | 2 |
| concepts[8].score | 0.49758461117744446 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q172847 |
| concepts[8].display_name | Peptide |
| concepts[9].id | https://openalex.org/C40767141 |
| concepts[9].level | 3 |
| concepts[9].score | 0.45701104402542114 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q285697 |
| concepts[9].display_name | Recombinant DNA |
| concepts[10].id | https://openalex.org/C523546767 |
| concepts[10].level | 2 |
| concepts[10].score | 0.30199915170669556 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q10876 |
| concepts[10].display_name | Bacteria |
| concepts[11].id | https://openalex.org/C202751555 |
| concepts[11].level | 2 |
| concepts[11].score | 0.26930367946624756 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q221681 |
| concepts[11].display_name | In vitro |
| concepts[12].id | https://openalex.org/C86803240 |
| concepts[12].level | 0 |
| concepts[12].score | 0.245433509349823 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[12].display_name | Biology |
| concepts[13].id | https://openalex.org/C55493867 |
| concepts[13].level | 1 |
| concepts[13].score | 0.06966090202331543 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[13].display_name | Biochemistry |
| concepts[14].id | https://openalex.org/C54355233 |
| concepts[14].level | 1 |
| concepts[14].score | 0.0 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q7162 |
| concepts[14].display_name | Genetics |
| concepts[15].id | https://openalex.org/C104317684 |
| concepts[15].level | 2 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[15].display_name | Gene |
| keywords[0].id | https://openalex.org/keywords/antimicrobial |
| keywords[0].score | 0.9130550622940063 |
| keywords[0].display_name | Antimicrobial |
| keywords[1].id | https://openalex.org/keywords/staphylococcus-aureus |
| keywords[1].score | 0.8435873985290527 |
| keywords[1].display_name | Staphylococcus aureus |
| keywords[2].id | https://openalex.org/keywords/microbiology |
| keywords[2].score | 0.6781163215637207 |
| keywords[2].display_name | Microbiology |
| keywords[3].id | https://openalex.org/keywords/antibiotics |
| keywords[3].score | 0.6436254978179932 |
| keywords[3].display_name | Antibiotics |
| keywords[4].id | https://openalex.org/keywords/antimicrobial-peptides |
| keywords[4].score | 0.6337056159973145 |
| keywords[4].display_name | Antimicrobial peptides |
| keywords[5].id | https://openalex.org/keywords/medicine |
| keywords[5].score | 0.6124887466430664 |
| keywords[5].display_name | Medicine |
| keywords[6].id | https://openalex.org/keywords/potency |
| keywords[6].score | 0.5679382681846619 |
| keywords[6].display_name | Potency |
| keywords[7].id | https://openalex.org/keywords/minimum-inhibitory-concentration |
| keywords[7].score | 0.5075477361679077 |
| keywords[7].display_name | Minimum inhibitory concentration |
| keywords[8].id | https://openalex.org/keywords/peptide |
| keywords[8].score | 0.49758461117744446 |
| keywords[8].display_name | Peptide |
| keywords[9].id | https://openalex.org/keywords/recombinant-dna |
| keywords[9].score | 0.45701104402542114 |
| keywords[9].display_name | Recombinant DNA |
| keywords[10].id | https://openalex.org/keywords/bacteria |
| keywords[10].score | 0.30199915170669556 |
| keywords[10].display_name | Bacteria |
| keywords[11].id | https://openalex.org/keywords/in-vitro |
| keywords[11].score | 0.26930367946624756 |
| keywords[11].display_name | In vitro |
| keywords[12].id | https://openalex.org/keywords/biology |
| keywords[12].score | 0.245433509349823 |
| keywords[12].display_name | Biology |
| keywords[13].id | https://openalex.org/keywords/biochemistry |
| keywords[13].score | 0.06966090202331543 |
| keywords[13].display_name | Biochemistry |
| language | en |
| locations[0].id | doi:10.5812/jjm.95948 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2481182593 |
| locations[0].source.issn | 2008-3645, 2008-4161 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2008-3645 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Jundishapur Journal of Microbiology |
| locations[0].source.host_organization | https://openalex.org/P4362561684 |
| locations[0].source.host_organization_name | Brieflands |
| locations[0].source.host_organization_lineage | https://openalex.org/P4362561684 |
| locations[0].source.host_organization_lineage_names | Brieflands |
| locations[0].license | cc-by-nc |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Jundishapur Journal of Microbiology |
| locations[0].landing_page_url | https://doi.org/10.5812/jjm.95948 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5051909064 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Seyedeh Fatemeh Jafari |
| authorships[0].countries | IR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I133903919 |
| authorships[0].affiliations[0].raw_affiliation_string | Students Research Committee, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran |
| authorships[0].institutions[0].id | https://openalex.org/I133903919 |
| authorships[0].institutions[0].ror | https://ror.org/056mgfb42 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I133903919 |
| authorships[0].institutions[0].country_code | IR |
| authorships[0].institutions[0].display_name | Arak University of Medical Sciences |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Seyedeh Fatemeh Jafari |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Students Research Committee, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran |
| authorships[1].author.id | https://openalex.org/A5080698288 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-8484-7166 |
| authorships[1].author.display_name | Ehsanollah Ghaznavi‐Rad |
| authorships[1].countries | IR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I133903919 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Medical Laboratory Sciences, Arak School of Paramedicine, Arak University of Medical Sciences, Arak, Iran |
| authorships[1].institutions[0].id | https://openalex.org/I133903919 |
| authorships[1].institutions[0].ror | https://ror.org/056mgfb42 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I133903919 |
| authorships[1].institutions[0].country_code | IR |
| authorships[1].institutions[0].display_name | Arak University of Medical Sciences |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Ehsanollah Ghaznavi-Rad |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Medical Laboratory Sciences, Arak School of Paramedicine, Arak University of Medical Sciences, Arak, Iran |
| authorships[2].author.id | https://openalex.org/A5061682510 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-9991-0869 |
| authorships[2].author.display_name | Shohreh Fahimirad |
| authorships[2].countries | IR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I133903919 |
| authorships[2].affiliations[0].raw_affiliation_string | Molecular and Medical Research Center, Arak University of Medical Sciences, Arak, Iran |
| authorships[2].institutions[0].id | https://openalex.org/I133903919 |
| authorships[2].institutions[0].ror | https://ror.org/056mgfb42 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I133903919 |
| authorships[2].institutions[0].country_code | IR |
| authorships[2].institutions[0].display_name | Arak University of Medical Sciences |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Shohreh Fahimirad |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Molecular and Medical Research Center, Arak University of Medical Sciences, Arak, Iran |
| authorships[3].author.id | https://openalex.org/A5044447375 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-3247-3289 |
| authorships[3].author.display_name | Hamid Abtahi |
| authorships[3].countries | IR |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I133903919 |
| authorships[3].affiliations[0].raw_affiliation_string | Molecular and Medical Research Center, Arak University of Medical Sciences, Arak, Iran |
| authorships[3].institutions[0].id | https://openalex.org/I133903919 |
| authorships[3].institutions[0].ror | https://ror.org/056mgfb42 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I133903919 |
| authorships[3].institutions[0].country_code | IR |
| authorships[3].institutions[0].display_name | Arak University of Medical Sciences |
| authorships[3].author_position | last |
| authorships[3].raw_author_name | Hamid Abtahi |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Molecular and Medical Research Center, Arak University of Medical Sciences, Arak, Iran |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.5812/jjm.95948 |
| open_access.oa_status | diamond |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Recombinant Oncorhyncin II Effect on the Treatment of Methicillin-Resistant Staphylococcus aureus Skin Infection |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11103 |
| primary_topic.field.id | https://openalex.org/fields/24 |
| primary_topic.field.display_name | Immunology and Microbiology |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2404 |
| primary_topic.subfield.display_name | Microbiology |
| primary_topic.display_name | Antimicrobial Peptides and Activities |
| related_works | https://openalex.org/W2606276788, https://openalex.org/W3107914937, https://openalex.org/W2978793169, https://openalex.org/W2954159082, https://openalex.org/W2894777053, https://openalex.org/W2378790910, https://openalex.org/W2753184995, https://openalex.org/W1994055913, https://openalex.org/W2356190564, https://openalex.org/W3169611954 |
| cited_by_count | 26 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 8 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 9 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 6 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 1 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 2 |
| locations_count | 1 |
| best_oa_location.id | doi:10.5812/jjm.95948 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2481182593 |
| best_oa_location.source.issn | 2008-3645, 2008-4161 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2008-3645 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Jundishapur Journal of Microbiology |
| best_oa_location.source.host_organization | https://openalex.org/P4362561684 |
| best_oa_location.source.host_organization_name | Brieflands |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4362561684 |
| best_oa_location.source.host_organization_lineage_names | Brieflands |
| best_oa_location.license | cc-by-nc |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Jundishapur Journal of Microbiology |
| best_oa_location.landing_page_url | https://doi.org/10.5812/jjm.95948 |
| primary_location.id | doi:10.5812/jjm.95948 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2481182593 |
| primary_location.source.issn | 2008-3645, 2008-4161 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2008-3645 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Jundishapur Journal of Microbiology |
| primary_location.source.host_organization | https://openalex.org/P4362561684 |
| primary_location.source.host_organization_name | Brieflands |
| primary_location.source.host_organization_lineage | https://openalex.org/P4362561684 |
| primary_location.source.host_organization_lineage_names | Brieflands |
| primary_location.license | cc-by-nc |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Jundishapur Journal of Microbiology |
| primary_location.landing_page_url | https://doi.org/10.5812/jjm.95948 |
| publication_date | 2020-05-09 |
| publication_year | 2020 |
| referenced_works | https://openalex.org/W2902814046, https://openalex.org/W2905489390, https://openalex.org/W2807152882, https://openalex.org/W2889819249, https://openalex.org/W2899121039, https://openalex.org/W2029862562, https://openalex.org/W2944467783, https://openalex.org/W2109938490, https://openalex.org/W2165943354, https://openalex.org/W1998662379, https://openalex.org/W2044458410, https://openalex.org/W2905300225, https://openalex.org/W2097171971, https://openalex.org/W2910918996, https://openalex.org/W1598844438, https://openalex.org/W4238338122, https://openalex.org/W2912996417, https://openalex.org/W4246625561, https://openalex.org/W2912673401, https://openalex.org/W2097962350, https://openalex.org/W2896262102, https://openalex.org/W2795932429, https://openalex.org/W4242899417, https://openalex.org/W1521039642, https://openalex.org/W4236541940, https://openalex.org/W2298649662, https://openalex.org/W2913723335, https://openalex.org/W2503826119, https://openalex.org/W2914023012 |
| referenced_works_count | 29 |
| abstract_inverted_index.a | 48, 65, 90, 239 |
| abstract_inverted_index.II | 62, 118, 141, 231 |
| abstract_inverted_index.In | 135 |
| abstract_inverted_index.S. | 28, 103, 170, 254 |
| abstract_inverted_index.as | 238 |
| abstract_inverted_index.be | 8, 89, 268 |
| abstract_inverted_index.by | 146, 157, 188 |
| abstract_inverted_index.in | 16, 93, 105, 175, 178, 250 |
| abstract_inverted_index.is | 5, 64 |
| abstract_inverted_index.of | 10, 23, 27, 51, 67, 85, 96, 110, 131, 152, 166, 184, 242, 253, 261 |
| abstract_inverted_index.on | 125 |
| abstract_inverted_index.to | 7, 36, 40, 100, 114, 127, 211, 223, 229, 246, 267 |
| abstract_inverted_index.225 | 193 |
| abstract_inverted_index.AMP | 63 |
| abstract_inverted_index.All | 216 |
| abstract_inverted_index.MIC | 190, 200 |
| abstract_inverted_index.The | 108, 150, 164, 182, 195 |
| abstract_inverted_index.and | 57, 72, 77, 83, 120, 177, 202 |
| abstract_inverted_index.are | 21, 47 |
| abstract_inverted_index.can | 88 |
| abstract_inverted_index.due | 99 |
| abstract_inverted_index.has | 208 |
| abstract_inverted_index.its | 122 |
| abstract_inverted_index.new | 38, 42, 49, 91, 240 |
| abstract_inverted_index.one | 9, 22 |
| abstract_inverted_index.the | 11, 17, 24, 81, 94, 129, 132, 139, 147, 158, 189, 199, 224, 251, 259, 262 |
| abstract_inverted_index.was | 113, 144, 155, 172, 192, 244 |
| abstract_inverted_index.MRSA | 126, 213, 220 |
| abstract_inverted_index.Skin | 19 |
| abstract_inverted_index.able | 210 |
| abstract_inverted_index.been | 209 |
| abstract_inverted_index.cell | 214 |
| abstract_inverted_index.have | 33, 247 |
| abstract_inverted_index.high | 58 |
| abstract_inverted_index.mice | 217 |
| abstract_inverted_index.most | 12 |
| abstract_inverted_index.seek | 37 |
| abstract_inverted_index.skin | 97, 256 |
| abstract_inverted_index.step | 92 |
| abstract_inverted_index.test | 191, 197, 201 |
| abstract_inverted_index.that | 204 |
| abstract_inverted_index.this | 111, 136, 153, 185, 205, 236 |
| abstract_inverted_index.vivo | 179 |
| abstract_inverted_index.with | 54, 69, 219 |
| abstract_inverted_index.(MIC) | 162 |
| abstract_inverted_index.drugs | 53 |
| abstract_inverted_index.group | 66 |
| abstract_inverted_index.known | 6 |
| abstract_inverted_index.study | 112 |
| abstract_inverted_index.test. | 163 |
| abstract_inverted_index.using | 174 |
| abstract_inverted_index.vitro | 176 |
| abstract_inverted_index.(AMPs) | 46 |
| abstract_inverted_index.(MRSA) | 4 |
| abstract_inverted_index.aureus | 3, 104, 171, 255 |
| abstract_inverted_index.effect | 74 |
| abstract_inverted_index.reduce | 212 |
| abstract_inverted_index.showed | 203 |
| abstract_inverted_index.study, | 138 |
| abstract_inverted_index.world. | 18 |
| abstract_inverted_index.against | 75, 169 |
| abstract_inverted_index.aureus. | 29 |
| abstract_inverted_index.effects | 124 |
| abstract_inverted_index.further | 265 |
| abstract_inverted_index.growth. | 215 |
| abstract_inverted_index.method. | 149 |
| abstract_inverted_index.minimum | 159 |
| abstract_inverted_index.natural | 52 |
| abstract_inverted_index.peptide | 143, 154, 186, 207, 233 |
| abstract_inverted_index.produce | 41, 115 |
| abstract_inverted_index.protein | 119, 168, 225 |
| abstract_inverted_index.require | 264 |
| abstract_inverted_index.results | 260 |
| abstract_inverted_index.studies | 266 |
| abstract_inverted_index.μg/mL. | 194 |
| abstract_inverted_index.Methods: | 134 |
| abstract_inverted_index.Results: | 181 |
| abstract_inverted_index.activity | 71, 165, 196, 234 |
| abstract_inverted_index.assessed | 156 |
| abstract_inverted_index.efficacy | 263 |
| abstract_inverted_index.evaluate | 121 |
| abstract_inverted_index.expected | 245 |
| abstract_inverted_index.fatality | 59 |
| abstract_inverted_index.infected | 218 |
| abstract_inverted_index.obtained | 187 |
| abstract_inverted_index.outcomes | 130, 249 |
| abstract_inverted_index.peptide, | 237 |
| abstract_inverted_index.peptides | 45, 68, 87 |
| abstract_inverted_index.positive | 248 |
| abstract_inverted_index.potency. | 60 |
| abstract_inverted_index.studies, | 235 |
| abstract_inverted_index.According | 228 |
| abstract_inverted_index.bacteria. | 79 |
| abstract_inverted_index.bacterial | 101 |
| abstract_inverted_index.confirmed | 198 |
| abstract_inverted_index.determine | 128 |
| abstract_inverted_index.objective | 109 |
| abstract_inverted_index.organisms | 15 |
| abstract_inverted_index.promotion | 84 |
| abstract_inverted_index.resistant | 102 |
| abstract_inverted_index.responded | 221 |
| abstract_inverted_index.treatment | 95 |
| abstract_inverted_index.Therefore, | 30, 80, 258 |
| abstract_inverted_index.challenged | 34 |
| abstract_inverted_index.confirmed. | 269 |
| abstract_inverted_index.generation | 50, 241 |
| abstract_inverted_index.hospitals. | 106 |
| abstract_inverted_index.infections | 20, 26, 98 |
| abstract_inverted_index.inhibitory | 160 |
| abstract_inverted_index.medicines. | 43 |
| abstract_inverted_index.pathogenic | 14 |
| abstract_inverted_index.positively | 222 |
| abstract_inverted_index.properties | 56 |
| abstract_inverted_index.strategies | 39 |
| abstract_inverted_index.treatment. | 133, 226 |
| abstract_inverted_index.Background: | 0 |
| abstract_inverted_index.Objectives: | 107 |
| abstract_inverted_index.Oncorhyncin | 61, 117, 140, 230 |
| abstract_inverted_index.constraints | 32 |
| abstract_inverted_index.development | 82 |
| abstract_inverted_index.improvement | 252 |
| abstract_inverted_index.infections. | 257 |
| abstract_inverted_index.potentially | 13 |
| abstract_inverted_index.recombinant | 116, 148, 167 |
| abstract_inverted_index.researchers | 35 |
| abstract_inverted_index.significant | 25 |
| abstract_inverted_index.synthesized | 145 |
| abstract_inverted_index.therapeutic | 31 |
| abstract_inverted_index.Conclusions: | 227 |
| abstract_inverted_index.antibiotics, | 243 |
| abstract_inverted_index.experimental | 137 |
| abstract_inverted_index.experiments. | 180 |
| abstract_inverted_index.investigated | 173 |
| abstract_inverted_index.Antimicrobial | 44, 142 |
| abstract_inverted_index.Gram-negative | 78 |
| abstract_inverted_index.Gram-positive | 76 |
| abstract_inverted_index.antimicrobial | 55, 73, 86, 123, 206, 232 |
| abstract_inverted_index.concentration | 161 |
| abstract_inverted_index.effectiveness | 151, 183 |
| abstract_inverted_index.Staphylococcus | 2 |
| abstract_inverted_index.bacteriostatic | 70 |
| abstract_inverted_index.Methicillin-resistant | 1 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 89 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 4 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.800000011920929 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.77913987 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |